- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Smaller, independent equity research firms are starting to cause bigger waves in the marketplace, but is the information really that valuable?
Despite tepid market reaction, and analyst skepticism, there might be some upside for TMO.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.